To the Editor: The study of treatment of Crohn disease by Dr Feagan and colleagues1 is important because smaller clinical trials are more susceptible to bias, are often less methodologically rigorous, and produce relatively less precise estimates of the true effect of treatment than large multicenter studies. However, the methodology of this study overlooked 2 potential sources of type II error.
Plotnikoff GA. Fatty Acid and Vitamin D Status in the EPIC Trials of Crohn Disease Treatment. JAMA. 2008;300(6):650. doi:10.1001/jama.300.6.650-a